Patents by Inventor Marc D. Better

Marc D. Better has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for recombinant peptide production
    Patent number: 7749731
    Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: July 6, 2010
    Assignee: XOMA Technology Ltd.
    Inventors: Marc D. Better, Patrick D. Gavit
  • Methods for Recombinant Peptide Production
    Publication number: 20090246831
    Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
    Type: Application
    Filed: June 13, 2007
    Publication date: October 1, 2009
    Applicant: XOMA Technology Ltd.
    Inventors: Marc D. Better, Patrick D. Gavit
  • Nucleic acids encoding Human Engineered heavy and light chain variable region sequences to Ep-CAM
    Publication number: 20080241126
    Abstract: Human engineered anti-Ep-CAM antibodies and various uses therefore are disclosed. These human engineered anti-Ep-CAM antibodies have high affinity binding to Ep-CAM with low immunogenicity.
    Type: Application
    Filed: November 2, 2007
    Publication date: October 2, 2008
    Applicant: XOMA TECHNOLOGY LTD.
    Inventors: Marc D. Better, Arnold H. Horwitz
  • Methods for recombinant peptide production
    Patent number: 7247454
    Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: July 24, 2007
    Assignee: XOMA Technology Ltd.
    Inventors: Marc D. Better, Patrick D. Gavit
  • Immunotoxins comprising ribosome-inactivating proteins
    Patent number: 7153932
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: December 26, 2006
    Assignee: Research Development Foundation
    Inventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
  • Methods and cells for expression of recombinant protein products under the transcriptional control of an inducible promoter
    Patent number: 6803210
    Abstract: The present invention relates generally to improved methods for the expression of recombinant protein products under the transcriptional control of an inducible promoter, such as an araB promoter, in bacterial host cells that are deficient in one or more of the active transport systems for the inducer of the inducible promoter. The present invention also relates to improved bacterial host cells that are deficient in one or more of the active transport systems for an inducer of an inducible promoter, such as arabinose for an araB promoter, and contain an expression vector encoding a recombinant polypeptide under the transcriptional control of the inducible promoter, such as an araB promoter.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: October 12, 2004
    Assignee: XOMA Technology Ltd.
    Inventor: Marc D. Better
  • Immunotoxins comprising ribosome-inactivating proteins
    Patent number: 6649742
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: November 18, 2003
    Assignee: XOMA Technology Ltd.
    Inventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
  • Methods for recombinant peptide production
    Publication number: 20030194782
    Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
    Type: Application
    Filed: December 20, 2002
    Publication date: October 16, 2003
    Applicant: XOMA Technology Ltd.
    Inventors: Marc D. Better, Patrick D. Gavit
  • Fusion proteins and polynucleotides encoding gelonin sequences
    Publication number: 20030166196
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Application
    Filed: April 23, 2002
    Publication date: September 4, 2003
    Applicant: XOMA Technology Ltd.
    Inventors: Marc D. Better, Stephen F. Carroll
  • Methods for recombinant peptide production
    Patent number: 6500648
    Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: December 31, 2002
    Assignee: Xoma Technology, Ltd.
    Inventors: Marc D. Better, Patrick D. Gavit
  • Production of chimeric antibodies with specificity to human tumor antigens
    Patent number: 6461824
    Abstract: The invention is directed to chimeric immunoglobulins that recognize a human tumor antigen bound by antibody, ING-2, ING-3, ING-4 or KM10, the production of such chimeric immunoglobulins, and their use.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 8, 2002
    Assignee: Xoma Technology Ltd.
    Inventors: Marc D. Better, Arnold H. Horwitz, Randy R. Robinson, Shau-Ping Lei, Changtung Paul Chang
  • Fusion proteins and polynucleotides encoding gelonin sequences
    Patent number: 6376217
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: April 23, 2002
    Assignee: Xoma Technology Ltd.
    Inventors: Marc D. Better, Stephen F. Carroll
  • Methods and cells for expression of recombinant protein products under the transcriptional control of an inducible promoter
    Publication number: 20020037552
    Abstract: The present invention relates generally to improved methods for the expression of recombinant protein products under the transcriptional control of an inducible promoter, such as an araB promoter, in bacterial host cells that are deficient in one or more of the active transport systems for the inducer of the inducible promoter. The present invention also relates to improved bacterial host cells that are deficient in one or more of the active transport systems for an inducer of an inducible promoter, such as arabinose for an araB promoter, and contain an expression vector encoding a recombinant polypeptide under the transcriptional control of the inducible promoter, such as an araB promoter.
    Type: Application
    Filed: March 19, 2001
    Publication date: March 28, 2002
    Inventor: Marc D. Better
  • Methods for recombinant peptide production
    Publication number: 20020009781
    Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
    Type: Application
    Filed: January 12, 2001
    Publication date: January 24, 2002
    Inventors: Marc D. Better, Patrick D. Gavit
  • Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
    Publication number: 20020006638
    Abstract: The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).
    Type: Application
    Filed: January 18, 2001
    Publication date: January 17, 2002
    Inventor: Marc D. Better
  • Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
    Patent number: 6274344
    Abstract: The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: August 14, 2001
    Assignee: XOMA Corporation
    Inventor: Marc D. Better
  • Methods for recombinant peptide production
    Patent number: 6242219
    Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells in which acid Lysis of the peptide occurs in cell culture media.
    Type: Grant
    Filed: March 18, 1999
    Date of Patent: June 5, 2001
    Assignee: Xoma (US) LLC
    Inventors: Marc D. Better, Patrick D. Gavit
  • Proteins encoding gelonin sequences
    Patent number: 6146850
    Abstract: The present invention provides purified proteins that contain gelonin amino acid sequences that have enzymatic activity.
    Type: Grant
    Filed: August 18, 1998
    Date of Patent: November 14, 2000
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Stephen F. Carroll
  • Immunotoxins comprising ribosome-inactivating proteins
    Patent number: 6146631
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: November 14, 2000
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
  • Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
    Patent number: 5851802
    Abstract: The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: December 22, 1998
    Assignee: Xoma Corporation
    Inventor: Marc D. Better